isotope.com
blue pipettes with blue background

Deuterated APIs and Advanced Intermediates for Pharmaceutical

Contact us to discuss your project
ISOAPI-D logo – The Power of Deuterium: Smarter, Stronger Therapeutics

Performance, Lifetime, and Supply Security with High-Purity Deuterated APIs and Advanced Intermediates for Pharmaceutical Innovation Compounds

ISOAPI-D™ products give pharmaceutical innovators a smarter, stronger foundation for therapeutic development. Whether you’re working on a novel API or optimizing an existing drug candidate, CIL’s expertise and global manufacturing are behind you. Our ISOAPI-D platform of deuterated materials delivers real advantages including extended half-life, improved metabolic profiles, and efficient production, so you can push therapies further and reduce development risk.

ISOAPI-D is a trademark of Cambridge Isotope Laboratories, Inc.

Resources

Stable Isotopes in Drug Development
Basic Starting Materials and Synthetic Intermediates
Deuterated Reagents and High-Purity Gases
Isotopic Enrichment and Species Abundance

Blog Articles

Beyond the Hype: How a Single Neutron Is Revolutionizing Drug Metabolism and API Design
Precision Engineering: The Synthesis, Scale-Up, and Quality Control of Deuterated APIs
Beyond Purity: Characterizing the Isotopologue Profile of a Deuterated API
From Bench to Blockbuster: The Definitive Clinical and Commercial Analysis of Deuterated Drugs

Recommended Products
ShOP All Products

ISOAPI-D Deuterated Compounds for Pharmaceutical Development

  • Robust and Secure Supply Chain: Large inventory of D2O and multi-ton in-house recycling capability. Facilities on three continents ensure robust, diversified supply and geopolitical stability. All facilities are ISO 9001 certified.
  • Bulk Manufacture: In-house bulk deuterated material production allows for reliable supply and high quality control of crucial starting materials, including fully traceable, tritium-free heavy water (D₂O).
  • Advanced intermediate synthetic expertise. Streamlined R&D timelines, reduced synthesis steps to lower costs, expedites time to market.
  • Discovery and optimization of next-generation therapeutics

Benefits of Deuterated APIs
in Drug Discovery

  • Extend Drug Half-life: Improve dosing convenience and patient compliance.
  • Enhance Metabolic Profiles: Achieve better therapeutic windows and reduced side effects.
  • Improved Pharmacokinetics: Behaves more favorably in the body with respect to absorption, distribution, metabolism, and excretion (ADME)
  • Potential for Greater Efficacy: May produce a stronger or more sustained therapeutic effect

ISOAPI-D Advantages From Early Research to Clinical Trials in Pharma

  • Robust quality control: Analytical methods and development in state-of-the-art facilities
  • Full Traceability and Compliance: Meet or exceed the highest industry standards, from early development through scale-up. Experienced in current licensing and deuterium export compliance.
  • cGMP Manufacturing: Reliable, large-scale supply of cGMP-grade materials, including full traceability with comprehensive documentation and familiarity with regulatory filing requirements.
  • Internal Standards and Tracers: High-purity labeled compounds for precise quantification in bioanalysis, ADME studies, and clinical trials.

Global Supply Chain Security for Pharmaceutical Innovation

Build your next-generation APIs on a foundation of certainty. With
ISOAPI-D, you  secure your supply chain and expedite your time to market by  utilizing CILs knowledge of advanced intermediate chemistry and stock of bulk deuterated raw materials.

Aerial view of an industrial facility with blue buildings, silos, and various equipment, surrounded by green fields and a water tower in the background.

Frequently Asked Questions (FAQs)

What is the difference between Isotopic Enrichment and  Species Abundance?

Isotopic enrichment refers to the percentage of deuterium at a specific, labeled position within a molecule. If a deuterated starting material is listed as having “99.5% D enrichment“ it means that for any given labeled position, there is a 99.5% probability of finding a deuterium atom and a 0.5% probability of finding a hydrogen atom.

Species abundance refers to the percentage of the total population of molecules that have a specific, complete isotopic composition.

For a more detailed explanation please see Application Note: Isotopic Enrichment vs. Species Abundance: A Critical Distinction

Isotopic Enrichment and Species Abundance

What are the steps required to return large scale D2O for recycling?

Please see link below for the detailed steps in returning D2O for recycling.

How do I determine which deuterated reagent is best for my synthesis?

Our scientific team can help identify the optimal labeling position, isotopic enrichment level, and synthetic route for your specific API development program. Reach out to us at cilsales@isotope.com.

Can custom-labeled compounds be synthesized?

Yes. Custom synthesis services are available for research, lead optimization, process development, and commercial manufacturing needs.

What isotopic enrichment levels are available?

Most products are available at enrichment levels ranging from approximately 98% to 99.9% deuterium incorporation, depending on the material.

Can you provide long-term supply agreements?

Yes. We work with customers to establish supply strategies that support clinical and commercial programs.

Do you support GMP manufacturing programs?

Yes. Depending on project requirements, GMP-compatible materials and documentation support can be provided.

Can you assist with regulatory documentation?

Our team can provide quality and technical documentation to support regulatory submissions when appropriate

Do youCan you support audits of manufacturing locations? support GMP manufacturing programs?

Yes. Qualified customers may request on-site or virtual audits, subject to confidentiality agreements, safety requirements, and scheduling availability.

References

Tatoueix , K.; Lepron, M.; Barboux, C.; et al. 2025. Unlocking the potential of hydrogen deuterium exchange via an iterative continuous-flow deuteration process. Nat Commun, 16(1), 1314-1322. PMID: 39900624
Schofield, K.; Maddern, S.; Zhang, Y.; et al. 2024. Deuterated reagents in multicomponent reactions to afford deuterium-labeled products. Beilstein J Org Chem, 20, 2270-2279. PMID: 39286789
Di Martino, R.M.C.; Maxwell, B.D.; Pirali, T. 2023. Deuterium in drug discovery: progress, opportunities and challenges. Nat Rev Drug Discov, 2(7), 562-584. PMID: 37277503
Mullard, A. 2022. First de novo deuterated drug poised for approval. Nat Rev Drug Discov, 21(9), 623-625. PMID: 35974147
Falb, E.; Ulanenko, K.; Tor, A.; et al. 2017. A highly efficient Suzuki-Miyaura methylation of pyridines leading to the drug pirfenidone and its CD3 version (SD-560). Green Chemistry, 21. Read article
Pepper Hamilton LLP. 2017. Deuterated drugs are new chemical entities. JDSUPRA® Read more
Mullard, A. 2016. Deuterated drugs draw heavier backing. Nat Rev Drug Discov, 15(4), 219-221. PMID: 27032821
2015. Drugs that live long will prosper. The Economist Science & Technology, Sept. 5 edition. economist.com. Read article
Tung, R. 2010. The development of deuterium-containing drugs. Innovations Pharm Technol, 32(32), 24-28. Read article